- Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
- Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
- Evaxion Announces Business Update and First Quarter 2024 Financial Results
- Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
- Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
- Evaxion und nicht offengelegter Kooperationspartner veröffentlichen vielversprechende Ergebnisse für EVX-B1-Impfstoff-Antigene gegen Staphylococcus aureus-Infektionen
- Evaxion et un collaborateur anonyme annoncent des résultats encourageants concernant les antigènes du vaccin EVX-B1 contre l'infection à staphylocoque doré
- Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
- Evaxion Announces Business Update and Full Year 2023 Financial Results
- Evaxion veranstaltet F&E-Tag und stellt das breite Potenzial seiner AI-Immunology™-Plattform vor
More ▼
Key statistics
On Monday, Evaxion Biotech A/S (EVAX:NAQ) closed at 2.47, 9.29% above its 52-week low of 2.26, set on Jun 17, 2024.
52-week range
Open | 2.92 |
---|---|
High | 2.97 |
Low | 2.26 |
Bid | 2.48 |
Offer | 2.81 |
Previous close | 2.47 |
Average volume | 22.86k |
---|---|
Shares outstanding | 521.51k |
Free float | -- |
P/E (TTM) | -- |
Market cap | 16.17m USD |
EPS (TTM) | -56.83 USD |
Data delayed at least 15 minutes, as of Jun 17 2024 21:00 BST.
More ▼